Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Venegas, E
- Garcia-Arnes, JA
- Cordido, F
- Aller, J
- Samaniego, ML
- Mir, N
- Sanchez-Cenizo, L
Grupos
Abstract
PurposeThe burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been previously studied. This study was aimed to determine the adherence to pegvisomant treatment in acromegaly patients in the real-world clinical practice setting in Spain.MethodsMulticenter, observational, descriptive, cross-sectional study in patients with acromegaly treated with pegvisomant for at least 12 months. Patient adherence was indirectly determined by Batalla and Haynes-Sackett questionnaires and directly by prescription record review. Additionally, treatment satisfaction was assessed by the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) and treatment convenience by an ad-hoc Pegvisomant questionnaire. Errors in reconstitution and administration process were determined by direct observation.Results108 patients were included in the analysis. Rates of adherence varied from 60.7 to 92.1% and did not correlate with disease control. Older patient age and alternative schedules other than daily pegvisomant dosing were associated with lower adherence. Treatment satisfaction and convenience was high, with a mean (SD) total SATMED-Q score of 74.615.4 over 100 and a total ad-hoc Pegvisomant questionnaire score of 71.2 +/- 15.2 over 100. 34.3% of patients made mistakes during the reconstitution /administration process.Conclusions p id=Par4 Patient adherence to pegvisomant was high (60.7-92.1%), but more than a third of the patients in the study made mistakes during the administration process, with a potential impact on disease control. Besides dosing compliance, correct administration of medication should be carefully assessed in these patients.
Datos de la publicación
- ISSN/ISSNe:
- 1386-341X, 1573-7403
- Tipo:
- Article
- Páginas:
- 137-145
- Factor de Impacto:
- 1,182 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Pituitary SPRINGER
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- Patient compliance; Medication adherence; Patient satisfaction; Pegvisomant; Medication errors; Acromegaly
Proyectos asociados
ESTUDIO FASE III, MULTICENTRICO, ALEATORIZADO, DOBLE CIEGO DE 48 SEMANAS, CON UN PERIDO INICIAL DE 12 SEMANAS CONTROLADO CON PLACEBO, PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE OSILODROSTAT EN PACIENTES CON ENFERMEDADES DE CUSHING.
Investigador Principal: ROSA CÁMARA GÓMEZ
CLCI699C2302 . 2016
ESTUDIO DE EXTENSIÓN, MULTICÉNTRICO, ABIERTO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO EN PACIENTES CON SÍNDROME DE CUSHING ENDÓGENO QUE HAYAN COMPLETADO UN ESTUDIO ANTERIOR DE OSILODROSTAT (LCI699) PATROCINADO POR NOVARTIS Y QUE EL INVESTIGADOR CONSIDERE QUE SE ESTÁN BENEFICIANDO DEL TRATAMIENTO CONTINUADO CON OSILODROSTAT.
Investigador Principal: ROSA CÁMARA GÓMEZ
CLCI699C2X01B . 2018
ESTUDIO OBSERVACIONAL, TRASVERSAL Y MULTICÉNTRICO PARA VALORAR EL CUMPLIMENTO TERAPÉUTICO CON SOMAVERT® EN PACIENTES CON ACROMEGALIA EN CONDICIONES DE PRÁCTICA CLÍNICA HABITUAL.
Investigador Principal: ROSA CÁMARA GÓMEZ
PFI-PEG-2014-01 . 2015
ESTUDIO MUNDIAL SOBRE EL CONTROL Y LAS COMPLICACIONES DEL HIPOTITUITARISMO (HYPOCCS).
Investigador Principal: JUAN FRANCISCO MERINO TORRES
B9R-MC-GDGA . 2011
Cita
Camara R,Venegas E,Garcia JA,Cordido F,Aller J,Samaniego ML,Mir N,Sanchez L. Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study. Pituitary. 2019. 22. (2):p. 137-145. IF:3,954. (2).